FDA Approves Foundayo: New Once-Daily Oral GLP-1 Pill for Weight Loss
The FDA approved Foundayo, a new once-daily oral GLP-1 pill, as an alternative to injectable Wegovy for weight loss on April 7, 2026. The approval marks a significant milestone in making weight-loss medications more accessible and convenient for patients. Health experts say the pill form could dramatically increase the number of people who benefit from GLP-1 therapy.
The U.S. Food and Drug Administration (FDA) approved Foundayo, a new once-daily oral GLP-1 (glucagon-like peptide-1) pill, as an alternative to injectable Wegovy for weight loss on April 7, 2026. The approval represents a significant advancement in obesity treatment, offering patients a more convenient pill-based option compared to weekly injections.
GLP-1 receptor agonists have revolutionized the treatment of obesity and type 2 diabetes in recent years, with injectable versions like Wegovy and Ozempic demonstrating remarkable effectiveness in clinical trials. However, many patients have been reluctant to use injectable medications, creating a significant unmet need for oral alternatives.
Foundayo's approval follows successful phase 3 clinical trials that demonstrated comparable weight loss outcomes to injectable GLP-1 medications. Participants in the trials lost an average of 15-18% of their body weight over 68 weeks, results that rival those seen with injectable versions.
Health experts are calling the approval a big deal for obesity treatment. "This could dramatically expand access to effective weight-loss therapy," said one endocrinologist. "Many patients who were hesitant about injections will now have a viable oral option."
The approval comes alongside news that the FDA also approved a higher-dose version of Wegovy (7.2 milligrams), potentially leading to even greater weight loss for patients who need additional support. Studies are also exploring whether weight loss can be maintained with fewer GLP-1 injections over time, which could reduce costs and side effects.
However, health experts caution that GLP-1 medications are not a cure-all and work best as part of a full approach to weight management that includes dietary changes, physical activity, and behavioral support. They also note that stopping GLP-1 medications may reverse their cardiovascular benefits, underscoring the importance of long-term treatment planning.
